Switzerland's Narcotics Regulation Jungle: Off-Label Use, Counterfoil Prescriptions, and Opioid Agonist Therapy in the French-Speaking Cantons.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_5D476E9B9CCC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Switzerland's Narcotics Regulation Jungle: Off-Label Use, Counterfoil Prescriptions, and Opioid Agonist Therapy in the French-Speaking Cantons.
Périodique
International journal of environmental research and public health
Auteur⸱e⸱s
Schmitt-Koopmann C., Baud C.A., Junod V., Simon O.
ISSN
1660-4601 (Electronic)
ISSN-L
1660-4601
Statut éditorial
Publié
Date de publication
14/12/2021
Peer-reviewed
Oui
Volume
18
Numéro
24
Pages
13164
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Résumé
The word "narcotic" is often first associated with "illicit drugs". Yet, many "narcotic" and psychotropic substances are, in fact, medicines. Controlled medicines (CM) are products that meet the legal definition of both a "narcotic" under the Swiss Narcotics Act and of a medicine under the Therapeutic Products Act. We aim to examine how similar and how different, respectively, the implementation of CM regulations is throughout French-speaking Switzerland. Based on a legal analysis of the cantonal regulations, we conducted semi-structured interviews with cantonal pharmacists and cantonal physicians. We asked them how they perceive and implement the federal legal requirements. We find that some of these requirements have fallen into disuse, notably the federal duty to notify off-label use of CM. We observe that counterfoil prescriptions in their current paper format are a veritable data graveyard in the sense that they are not actively used to monitor or supervise the market. Moreover, we detect different conditions for opioid agonist treatment authorization. Some cantons require additional physicians' training or written commitments by the person treated. Our mapping of the CM regulation implementation can serve as a basis for cantons to review their practices.
Mots-clé
Analgesics, Opioid, Humans, Narcotics/therapeutic use, Off-Label Use, Prescriptions, Switzerland, administration, controlled medicines, counterfoil prescriptions, narcotics, off-label, opioid agonist treatments, opioid informed consent, opioids, public health, regulation
Pubmed
Web of science
Open Access
Oui
Financement(s)
Fonds national suisse / 182477
Création de la notice
15/12/2021 16:36
Dernière modification de la notice
22/01/2022 7:32
Données d'usage